My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 101

    1.

    Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy.

    Duvillard L, Florentin E, Lizard G, Petit JM, Galland F, Monier S, Gambert P, Vergès B.

    Diabetes Care. 2003 May;26(5):1540-4.PMID: 12716819 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus.

    Duvillard L, Pont F, Florentin E, Gambert P, Vergès B.

    Diabetologia. 2000 Jan;43(1):27-35.PMID: 10663213 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effect of insulin treatment on plasma oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients.

    Galland F, Duvillard L, Petit JM, Lagrost L, Vaillant G, Brun JM, Gambert P, Vergès B.

    Diabetes Metab. 2006 Dec;32(6):625-31.PMID: 17296517 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    5.

    Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.

    Habib SS, Aslam M, Naveed AK, Razi MS.

    Saudi Med J. 2006 Feb;27(2):174-80.PMID: 16501671 [PubMed - indexed for MEDLINE]Related articles

    6.

    Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.

    Olansky L, Marchetti A, Lau H.

    Clin Ther. 2003;25 Suppl B:B64-80. Review.PMID: 14553867 [PubMed - indexed for MEDLINE]Related articles

    7.

    Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

    Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.

    Eur J Endocrinol. 2008 Jan;158(1):35-46.PMID: 18166815 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients.

    Scognamiglio R, Negut C, de Kreutzenberg SV, Tiengo A, Avogaro A.

    Diabetes Care. 2006 Jan;29(1):95-100.PMID: 16373903 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    10.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.

    Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI.

    Diabet Med. 2005 Mar;22(3):316-22.PMID: 15717881 [PubMed - indexed for MEDLINE]Related articles

    12.

    Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

    Derosa G, Fogari E, D'Angelo A, Cicero AF, Salvadeo SA, Ragonesi PD, Ferrari I, Gravina A, Fassi R, Fogari R.

    J Clin Pharm Ther. 2007 Jun;32(3):261-8.PMID: 17489878 [PubMed - indexed for MEDLINE]Related articles

    13.

    Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients.

    Mayorov AY, Naumenkova IV, Antsiferov MB, Dedov II.

    Diabetes Res Clin Pract. 2005 Jun;68 Suppl1:S54-9. Epub 2005 Mar 25.PMID: 15955377 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.

    Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM.

    Metabolism. 2004 Feb;53(2):159-64.PMID: 14767866 [PubMed - indexed for MEDLINE]Related articles

    15.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    16.

    Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.

    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.

    J Diabetes Complications. 2007 Jan-Feb;21(1):20-7.PMID: 17189870 [PubMed - indexed for MEDLINE]Related articles

    17.

    Comparison of apolipoprotein B100 metabolism between continuous subcutaneous and intraperitoneal insulin therapy in type 1 diabetes.

    Duvillard L, Florentin E, Baillot-Rudoni S, Lalanne-Mistrich ML, Brun-Pacaud A, Petit JM, Brun JM, Gambert P, Vergès B.

    J Clin Endocrinol Metab. 2005 Oct;90(10):5761-4. Epub 2005 Aug 9.PMID: 16091481 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.

    Diabetes. 2003 Aug;52(8):1943-50.PMID: 12882909 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Natural honey lowers plasma glucose, C-reactive protein, homocysteine, and blood lipids in healthy, diabetic, and hyperlipidemic subjects: comparison with dextrose and sucrose.

    Al-Waili NS.

    J Med Food. 2004 Spring;7(1):100-7.PMID: 15117561 [PubMed - indexed for MEDLINE]Related articles

    20.

    Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

    Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity